RAF 265

Cat. No. 6015new

RAF 265 C24H16F6N6O [927880-90-8]

Price and Availability

For RAF 265 pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Alternative Name: CHIR 265

Chemical Name: 1-Methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine

Biological Activity

Raf kinase and VEGFR-2 inhibitor. Inhibits c-Raf, wild type B-Raf and mutant B-Raf (V600E). Cytotoxic in certain melanoma cells lines. Effects enhanced by protein kinase D3 inhibition, preventing reactivation of MAPK signaling and increasing caspase activity. Orally bioavailable.

Technical Data

M.Wt:
518.41
Formula:
C24H16F6N6O
Solubility:
Soluble to 100 mM in DMSO and to 20 mM in ethanol
Purity:
>98 %
Storage:
Store at -20°C
CAS No:
927880-90-8

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Product Datasheet / Safety Data Sheet

Chen et al (2011) Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling. Cancer Res. 71 4280. PMID: 21527556 .

If you know of a relevant reference for this product please let us know.

Citations are publications that use Tocris products.

Do you know of a great paper that uses RAF 265 from Tocris? If so please let us know.

View Related Products by Product Action

Keywords: RAF 265, supplier, RAF265, Raf, kinases, inhibitors, inhibits, B-Raf, c-Raf, VEGFR2, vascular, endothelial, growth, factor, cytotoxic, MAPK, Tocris Bioscience, Raf Kinase Inhibitor products

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide

Cancer Research Product Guide

Our Cancer Research Guide highlights over 750 products for cancer research. Request copy or view PDF today.

divider line

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Kinase Inhibitor Toolbox

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

divider line

Kinases Product Listing

Kinases Product Listing

Our Kinase listing highlights over 400 products for kinase research. Request copy or view PDF today.

divider line

Immunology Guide

Immunology Product Listing

Our Immunology listing highlights over 190 products for immunology research. Request copy or view PDF today.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Life Science Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance. Request copy today.

divider line

New Products in this Area

PF 06409577

Potent and selective allosteric activator of AMPK

Perifosine

PKB/Akt inhibitor; also modulates Kv2.1 current

CZC 25146

Potent LRRK2 inhibitor

Ro 3280

Potent and selective PLK1 inhibitor

RMM 46

MSK/RSK family kinase inhibitor

LTURM 34

Potent DNA-PK inhibitor

MLi-2

Potent and selective LRRK2 inhibitor

LTURM 36

PI 3-kinase δ inhibitor

PI 3065

Potent and selective PI 3-kinase p110δ inhibitor

AZ PFKFB3 67

Potent and selective PFKFB3 inhibitor

STOCK2S 26016

Lysine deficient protein kinase (WNK) signaling inhibitor

rac-CCT 250863

Potent Nek2 inhibitor

Roscovitine

Potent, selective cyclin-dependent kinase inhibitor

Enzastaurin

Potent PKCβ inhibitor

BMS 265246

Potent cdk1/2 inhibitor

Autocamtide-2-related inhibitory peptide, myristoylated

CaM kinase II inhibitor; enhanced cell permeable derivative of Autocamtide-2-related inhibitory peptide

MP A08

Selective ATP competitive SphK1 and 2 inhibitor; cell permeable

Sign-up for new product e-alerts
divider line

LinkedIn Updates

Follow Tocris on LinkedIn

Follow us on LinkedIn!

Visit our LinkedIn page for the latest Tocris news, events and updates.